TLR3 and neoplasm: Our in vitro data clearly demonstrate that TL-532 induces TLR3-specific immunogenic cancer cell death via caspase-mediated apoptosis, and reduces tumor cell viability at similar level compared to Poly(A:U) HMW [15, 24] in all the tested cancer cells, while it is well tolerated in primary human cells leading to a wide therapeutic index.